Accordingly, several molecular inhibitors binding to fibroblast growth factor receptor (FGFR) 2 or isocitrate dehydrogenase 1 or 2 (IDH1 or 2) were developed for management of advanced iCCA carrying FGFR2 fusion or IDH1/2 mutation [10]. Here, IDH1 is linked to infantile convulsions and choreoathetosis.